Results 21 to 30 of about 1,013 (109)

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

, 2022
The third-generation anaplastic lymphoma tyrosine kinase inhibitor (ALK-TKI) lorlatinib has a unique side effect profile that includes hypercholesteremia and hypertriglyceridemia in >80% of lung cancer patients.
Elisabet Cuyàs, Menendez, Javier A., Javier A. Menendez, Encinar, José Antonio, Sara Verdura, Joven, Jorge, Bosch-Barrera, Joaquim, Joaquim Bosch-Barrera, Fernández-Arroyo, Salvador, Menéndez Menéndez, Javier Abel, Salvador Fernández-Arroyo, Jorge Joven, José Antonio Encinar, Bosch Barrera, Joaquim, Cuyàs, Elisabet, Verdura, Sara   +15 more
core   +2 more sources

Population pharmacokinetic model with time‐varying clearance for lorlatinib using pooled data from patients with non‐small cell lung cancer and healthy participants

CPT: Pharmacometrics & Systems Pharmacology, 2021
Lorlatinib, a selective inhibitor of anaplastic lymphoma kinase (ALK) and c‐ROS oncogene 1 (ROS1) tyrosine kinase, is indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC) following progression on crizotinib and at ...
Joseph Chen, Brett Houk, Yazdi K. Pithavala, Ana Ruiz‐Garcia   +3 more
doaj   +1 more source

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

JTO Clinical and Research Reports, 2023
Introduction: Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than ...
Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD   +21 more
doaj   +1 more source

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

JTO Clinical and Research Reports, 2021
Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R.
Viola W. Zhu, MD, PhD, Misako Nagasaka, MD, Russell Madison, BA, Alexa B. Schrock, PhD, Jean Cui, PhD, Sai-Hong Ignatius Ou, MD, PhD   +5 more
doaj   +1 more source

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece [PDF]

Journal of Health Economics and Outcomes Research, 2022
**Background:** Non-small cell lung cancer (NSCLC), which accounts for about 80%-85% of lungcancer cases, is a leading cause of cancer-related death worldwide.
George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba   +6 more
doaj   +2 more sources

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Respirology Case Reports, 2021
Alectinib treatment is effective in patients with anaplastic lymphoma kinase (ALK) gene rearrangement‐positive non‐small cell lung cancer (NSCLC; hereafter ALK‐positive NSCLC) who exhibit central nervous system (CNS) relapse and poor performance status ...
Kota Sasaki, Yusuke Yokota, Toshihito Isojima, Mayumi Fujii, Kengo Hasui, Yu Chen, Kensuke Saito, Takenori Takahata, Seiko Kindaichi, Atsushi Sato   +9 more
doaj   +1 more source

Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC

Cell Death Discovery, 2022
Lorlatinib is a promising third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been approved for treating ALK-positive non-small-cell lung cancer (NSCLC) patients with previous ALK-TKI treatment failures.
Conghua Lu, Rui Yu, Chong Zhang, Caiyu Lin, Yuanyao Dou, Di Wu, Yonghong Pan, Tao Peng, Huan Tang, Rui Han, Yong He   +10 more
doaj   +1 more source

Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats [PDF]

Drug Design, Development and Therapy
Cong Xie,1,2,* Tongshu Guan,1,2,* Jin Huang,1,2 Jiayu Chen,1,2 Yilei Li,1,2 Ping Zheng1,2 1Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2Department of Pharmacy, Nanfang ...
Xie C, Guan T, Huang J, Chen J, Li Y, Zheng P   +5 more
doaj   +1 more source

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

, 2023
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib.
Ami V. Desai, Judith G. Villablanca, Chesler, L, Hiroyuki Shimada, Thurm, HC, Desai, AV, Macy, ME, Esther R. Berko, Ghazarian, S, Goldsmith, KC, Marshall, L, Yael P. Mossé, Krytska, K, Maris, JM, Liyanage, M, Shusterman, S, Susan G. Groshen, Joseph Chen, Marachelian, A, Patricia T. Acharya, Kimberly Kayser, Kateryna Krytska, Rajen Mody, Vo, K, Groshen, SG, Matthay, KK, Lynley Marshall, Lisa States, Daniel A. Morgenstern, Katherine K. Matthay, Shimada, H, Pinto, N, Susan Ghazarian, Mody, R, Gerson Peltz, Kieuhoa Vo, Kayser, K, Marlon Liyanage, Fariba Goodarzian, Villablanca, JG, Lai, LM, Chen, J, John M. Maris, Acharya, PT, Yueh-Yun Chi, Mossé, YP, Julie R. Park, Park, JR, States, L, Granger, M, Meaghan Granger, Araz Marachelian, Malvar, J, Lillian M. Lai, Pawel, B, Holger C. Thurm, Kelly C. Goldsmith, Schleiermacher, G, Peltz, G, Louis Chesler, Margaret E. Macy, Goodarzian, F, Jemily Malvar, Navin Pinto, Chi, Y-Y, Suzanne Shusterman, Morgenstern, DA, Gudrun Schleiermacher, Berko, ER, Bruce Pawel   +69 more
core   +1 more source

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Frontiers in Oncology, 2021
IntroductionRecently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced non-small cell lung cancer (NSCLC ...
SiNi Li, SiNi Li, JianHe Li, LiuBao Peng, YaMin Li, YaMin Li, XiaoMin Wan   +6 more
doaj   +1 more source